Skip to main content

Table 7 Efficacy by visit and genotype in the dosage compliant population*

From: Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial

Group; N AC-1202 Placebo Difference (95% CI) p-value
  Day 45 Mean Change From Baseline
ADAS-Cog     
   DC; 46AC, 50PL -0.964 1.639 2.60(0.39, 4.81) 0.0215
   APOE4(-); 16AC, 20PL -3.063 3.198 6.26(2.59, 9.94) 0.0011
   APOE4(+); 24AC, 24PL 0.361 0.750 0.39(-2.77, 3.55) 0.8073
MMSE     
   DC; 46AC, 50PL 0.326 -0.220 0.55(-0.57, 1.66) 0.3342
   APOE4(-); 16AC, 20PL -0.313 0.350 0.66(-1.12, 2.45) 0.4622
   APOE4(+); 24AC, 24PL 0.500 -0.917 1.42(-0.12, 2.95) 0.0701
CGIC     
   DC; 44AC, 48PL 4.114 4.313 0.20(-0.32, 0.72) 0.4481
   APOE4(-); 16AC, 19PL 4.063 4.895 0.83(0.00, 1.66) 0.0500
   APOE4(+); 22AC, 23PL 4.182 3.652 0.53(-0.20, 1.26) 0.1533
  Day 90 Mean Change From Baseline
ADAS-Cog     
   DC; 44AC, 48PL -1.182 1.076 2.26(-0.14, 4.65) 0.0641
   APOE4(-); 16AC, 19PL -3.854 1.472 5.33(1.55, 9.11) 0.0063
   APOE4(+); 22AC, 24PL 0.909 0.833 0.08(-3.21, 3.36) 0.9635
MMSE     
   DC; 44AC, 48PL -0.136 -0.271 0.13(-1.1, 1.36) 0.8275
   APOE4(-); 16AC, 19PL -0.125 0.789 0.91(-1.09, 2.92) 0.3656
   APOE4(+); 22AC, 24PL -0.136 -1.083 0.95(-0.79, 2.69) 0.2820
CGIC     
   DC; 43AC, 48PL 4.535 4.521 0.01(-0.56, 0.59) 0.9613
   APOE4(-); 16AC, 19PL 4.125 4.474 0.35(-0.59, 1.29) 0.4613
   APOE4(+); 21AC, 24PL 4.714 4.375 0.34(-0.49, 1.17) 0.4158
  Day 104 Mean Change From Baseline
ADAS-Cog     
   DC; 43AC, 47PL -0.969 0.682 1.65(-0.75, 4.05) 0.1751
   APOE4(-); 16AC, 19PL -1.875 1.389 3.26(-0.72, 7.25) 0.1070
   APOE4(+); 21AC, 23PL 0.111 0.449 0.34(-3.21, 3.88) 0.8498
MMSE     
   DC; 43AC, 47PL 0.186 -0.766 0.95(-0.48, 2.38) 0.1901
   APOE4(-); 16AC, 19PL -0.313 0.000 0.31(-2.03, 2.66) 0.7916
   APOE4(+); 21AC, 23PL 0.524 -1.565 2.09(0.00, 4.18) 0.0499
CGIC     
   DC; 42AC, 46PL 4.667 4.804 0.14(-0.42, 0.70) 0.6248
   APOE4(-); 15AC, 19PL 4.267 4.895 0.63(-0.24, 1.50) 0.1547
   APOE4(+); 21AC, 22PL 4.857 4.455 0.40(-0.37, 1.17) 0.3002
  1. DC = Dosage Compliant; AC = AC-1202; PL = Placebo.
  2. *2 way ANOVA calculated using PROC GLM Type 3 SS. P-values of differences of the type 3 SS LSMEANS.
  3. CGIC Mean Total scores at Days 45, 90 and 104.
  4. Note, since this table uses non-imputed data, the number of subjects varies by Visit.